Related Experiment Videos
Interruption of tumor-associated platelet consumption with platelet enzyme inhibitors
Abstract:
Twenty dogs with naturally occurring metastatic tumors were treated with anticoagulants (Warfarin) or platelet enzyme inhibitor drugs (dipyridamole, dipyridamole plus aspirin, RA233, sulfinpyrazone, or a combination of RA233 and sulfinpyrazone) to determine if tumor-related reductions in platelet survival and concentration could be reversed. Anticoagulation was ineffective, while platelet enzyme inhibitors were able to produce improvements in platelet survival. Of the 18 dogs with metastatic tumor treated with platelet enzyme inhibitors, only 5 (28%) showed a reduction in platelet survival during the first week of observation on therapy compared to their baseline survivals. This is significantly different than the decreases in platelet survivals observed in 8 of 10 untreated dogs (80%) with metastatic tumor observed for the same interval. Furthermore, 8 of the 18 treated dogs (44%) had platelet survivals within 2 standard deviations of normal, compared to only 1 of 10 untreated dogs. Of the 8 dogs with normal platelet survivals, 6 were treated with a combination of a phosphodiesterase inhibitor (RA233 or dipyridamole) and a cyclooxygenase inhibitor (sulfinpyrazone or aspirin). The combination of RA233 and sulfinpyrazone was the best drug program tested and resulted in normal platelet survivals in 63% and improved platelet counts in 75% of the animals treated. Thus, platelet enzyme inhibitors with different mechanisms of action may have a synergistic effect in reversing the abnormal platelet hemostasis found in a variety of spontaneously occurring canine neoplasms.
Insights
Platelet enzyme inhibitors, particularly combinations, effectively reversed abnormal platelet function in dogs with metastatic tumors. Anticoagulants were ineffective, highlighting the potential of targeted platelet therapies in cancer care.
Area of Science:
- Veterinary Oncology
- Hematology
- Pharmacology
Background:
- Naturally occurring metastatic tumors in dogs can lead to abnormal platelet survival and concentration.
- Understanding and reversing these hemostatic changes is crucial for managing cancer in companion animals.
Purpose of the Study:
- To evaluate the efficacy of anticoagulants and platelet enzyme inhibitors in reversing tumor-associated platelet abnormalities in dogs.
- To identify specific drug combinations with synergistic effects on platelet hemostasis.
Main Methods:
- Twenty dogs with metastatic tumors were treated with Warfarin (anticoagulant) or various platelet enzyme inhibitors (dipyridamole, aspirin, RA233, sulfinpyrazone, or combinations).
- Platelet survival and concentration were monitored to assess treatment response.
- Comparison of outcomes between treated and untreated control groups.
Main Results:
- Anticoagulation with Warfarin showed no significant improvement.
- Platelet enzyme inhibitors improved platelet survival in treated dogs compared to untreated controls.
- Combinations of phosphodiesterase inhibitors (RA233, dipyridamole) and cyclooxygenase inhibitors (sulfinpyrazone, aspirin) demonstrated the most significant positive effects, normalizing platelet survival in 63% and improving counts in 75% of animals.
Conclusions:
- Platelet enzyme inhibitors are effective in reversing abnormal platelet hemostasis associated with canine neoplasms.
- Combination therapy, particularly involving drugs with different mechanisms of action, offers a synergistic approach for managing platelet dysfunction in cancer-bearing dogs.
- This study suggests a promising therapeutic strategy for improving hemostasis in dogs with metastatic disease.